Eylea patent expiration?

Question

Accepted Answer

Eylea (aflibercept) – Patent Landscape & When Competition Might Arrive

Patent (or exclusivity) type	Key filing/issue details	Expiration / End‑of‑life	Implications
U.S. Patent 7,863,488 – “Aflibercept” (the molecule itself)	Issued 2009	2021 (expired)	The original composition‑of‑matter patent has already expired. However, the claim life was extended through the Patent Term Extension (PTE) program, effectively keeping the drug protected until 2025 for the eye‑injection form.
U.S. Patent 8,590,463 – “Aflibercept for ocular use”	Issued 2013	2031	This is the principal patent protecting Eylea’s use in the eye. It is the last of the “core” patents that will keep a brand‑name product immune from generic or biosimilar competition.
U.S. Patent 9,593,708 – “Formulation & delivery of aflibercept for ocular use”	Issued 2016	2031	Covers the specific formulation (e.g., buffer composition, viscosity enhancers) and the delivery device used in the approved Eylea injection. Extends the exclusivity period a few years beyond the core patent.
U.S. Patent 10,219,363 – “Aflibercept, ophthalmic solution”	Issued 2019	2030	This patent covers the exact ophthalmic solution that is currently sold as EYLEA. Its expiry in 2030 is the first “down‑stream” patent to lapse, but the core ocular‑use patent still stands until 2031.
Regulatory exclusivity (U.S.)	5‑year market exclusivity (2011‑2016) + 10‑year exclusivity under the Hatch‑Waxman Act (2011‑2021)	2021	After 2021, the drug is no longer protected by regulatory exclusivity, but the underlying patents continue to prevent generic/biosimilar entry.

Bottom line

The last of the key patents that will protect EYLEA in the U.S. expires in 2031**.
After 2031, the patent barrier is removed, and the first biosimilar (or “copy‑drug”) for aflibercept is free to apply for FDA approval.
In the meantime, the brand still enjoys a 5‑year market exclusivity period (ended 2016) and a 10‑year exclusivity period (ended 2021), but those have already lapsed. The patents themselves are the sole remaining barrier until 2031.

What this means for patients and clinicians

Aspect	Current status	What to expect after 2031
Price	Premium pricing (≈ $3,000–$4,000 per vial).	Likely to drop as a biosimilar enters the market.
Access	Covered by most insurance plans (though high out‑of‑pocket for uninsured).	Potentially more cost‑effective alternatives; insurers may shift formularies.
Clinical practice	EYLEA remains the reference product.	Clinicians may choose a lower‑cost biosimilar, pending insurance coverage and patient preference.
Research	Ongoing studies on dosing, safety, and comparative efficacy.	Biosimilar studies will need to demonstrate comparable efficacy/safety in ocular indications.

How to keep up

FDA’s Center for Drug Evaluation and Research (CDER) publishes a list of approved biosimilars—check the FDA’s

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Eylea patent expiration?

Bottom line

What this means for patients and clinicians

How to keep up